TBPH — Theravance Biopharma, Inc.

Theravance Biopharma (TBPH) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Sales: YUPELRI achieved net sales of $71.4 million in Q3 2025, a 15% increase year-over-year, driven by strong demand and improved net pricing.
• Profitability: The company reported record brand profitability for YUPELRI, achieving non-GAAP breakeven for the quarter.
• Cash Position: Theravance ended the quarter with approximately $333 million in cash and no debt.
• Collaboration Revenue: Increased to $20 million, up 19% year-over-year.
• Operating Expenses: Excluding share-based compensation, operating expenses were $22 million, reflecting a decline in R&D costs as Cyprus trial enrollment completed.

2. Strategic Updates and Business Highlights:

• YUPELRI Performance: Continued strong demand growth and profitability, with a milestone payment of $25 million from Viatris expected if Q4 sales reach $250 million.
• Ampreloxetine Development: Progressing towards pivotal Phase III Cyprus trial data readout expected in early 2026, viewed as a potential value inflection point.
• New Initiatives: Launched a disease education campaign for healthcare professionals focusing on neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy (MSA).
• Upcoming KOL Event: Scheduled for December 8 to discuss the unmet medical need in MSA and the potential of ampreloxetine.

3. Forward Guidance and Outlook:

• Q4 Expectations: The company anticipates achieving near-term milestones totaling $75 million, with $50 million from Trelegy and $25 million from YUPELRI.
• 2025 Financial Guidance: Reiterating expense guidance, expecting results to remain consistent in Q4, excluding the anticipated milestone payments.
• Long-term Outlook: Positive momentum heading into 2026, with a focus on the upcoming Cyprus data readout and continued growth of YUPELRI.

4. Bad News, Challenges, or Points of Concern:

• Dependence on Cyprus Trial Results: The success of ampreloxetine is critical; any negative outcome could impact future growth and strategic direction.
• Market Competition: The company must navigate competitive pressures in the respiratory market, particularly for YUPELRI.
• Cost Management: While operating expenses are currently under control, the launch of ampreloxetine could introduce new costs that need to be managed effectively.

5. Notable Q&A Insights:

• Capital Return Strategy: Management emphasized the importance of financial strength and indicated that decisions regarding capital returns to shareholders will be made post-Cyprus results.
• Pipeline Focus: The management reiterated a commitment to focus on YUPELRI and ampreloxetine, with potential future evaluations of other pipeline assets post-Cyprus success.
• Cyprus Study Enrollment: While specific enrollment numbers were not disclosed, management expressed confidence in the study's design and its ability to detect treatment differences.

Overall, Theravance Biopharma demonstrated strong financial performance in Q3 2025, with a focus on the upcoming pivotal trial results for ampreloxetine, while maintaining a robust cash position and strategic growth in YUPELRI.